<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591630</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1018</org_study_id>
    <secondary_id>NCI-2012-01753</secondary_id>
    <nct_id>NCT00591630</nct_id>
  </id_info>
  <brief_title>Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation</brief_title>
  <official_title>Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM&#xD;
      chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more&#xD;
      effective than the combination of BEAM and rituximab alone in patients with lymphoma who&#xD;
      receive a stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      90Y Zevalin is designed to attach to lymphoma cells, and destroy the cells using a radiation&#xD;
      particle that is attached to it.&#xD;
&#xD;
      111In Zevalin is like 90Y Zevalin, but the radioactive particle that is attached to it does&#xD;
      not kill lymphoma cells. The radioactive particle makes the drug able to be seen inside your&#xD;
      body. It is being used in this study to predict how fast the study drug will travel in the&#xD;
      body and how long the drug stays in the body.&#xD;
&#xD;
      Carmustine, etoposide, cytarabine, and melphalan (BEAM) are designed to kill lymphoma cells&#xD;
      by damaging the cells DNA.&#xD;
&#xD;
      Rituximab is designed to attach to lymphoma cells, which may cause them to die.&#xD;
&#xD;
      Study Groups 1 and 2:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the toss of a coin) to 1 of 2 groups. You will have an equal chance of being assigned to&#xD;
      each group. Group 1 will receive 90Y Zevalin along with rituximab and BEAM therapy. Group 2&#xD;
      will receive rituximab and BEAM therapy. You and the study staff will know which group you&#xD;
      are in.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are in Group 1, you will receive rituximab through a needle in your vein (over 4-5&#xD;
      hours) followed by 111In Zevalin by vein (over 15 minutes). A nuclear scan will be done&#xD;
      within the following 40 to 48 hours to see how the drug is traveling through your body.&#xD;
&#xD;
      If intolerable side effects are not shown by the scans, you will receive rituximab (over 4-5&#xD;
      hours) and 90Y Zevalin (over 15 minutes) through a needle in your vein 7 days after the 111In&#xD;
      Zevalin infusion.&#xD;
&#xD;
      You will begin BEAM chemotherapy 7 days after the second 90Y Zevalin infusion.&#xD;
&#xD;
      BEAM Chemotherapy:&#xD;
&#xD;
      Both groups will have 7 days of BEAM combination chemotherapy.&#xD;
&#xD;
        -  On Day 1, you will receive carmustine through a needle in your vein over 1 hour.&#xD;
&#xD;
        -  On Days 2-5 you will receive cytarabine by vein (over 1 hour) followed by etoposide&#xD;
           (over 3 hours). Both infusions will be repeated every 12 hours on Days 2-5.&#xD;
&#xD;
        -  On Day 6 you will be given melphalan by vein over 30 minutes.&#xD;
&#xD;
        -  On Day 7 the stem cells that were collected earlier from you will be given back&#xD;
           (&quot;transplanted&quot;) through a catheter over 30-45 minutes.&#xD;
&#xD;
        -  You will also receive rituximab by vein (over 5-7 hours) on Day 8.&#xD;
&#xD;
      You will receive rituximab (over 4-5 hours) 7 days after the stem cell transplant. You will&#xD;
      receive G-CSF by injection once a day starting 7 days after the stem cell transplant until&#xD;
      your blood counts return to a normal level. You should stay in the Houston area for about 2-4&#xD;
      weeks after the transplant.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      At about 1 month after the transplant you will have x-rays, CT scans, and positron emission&#xD;
      tomography (PET) scans. You will also have a bone marrow aspirate and biopsy to check the&#xD;
      status of the disease.&#xD;
&#xD;
      Blood (about 1 tablespoon) will be drawn once a day while you are in the hospital to check&#xD;
      your blood counts.&#xD;
&#xD;
      Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, and x-rays may be&#xD;
      done as needed to track the effects of the transplant.&#xD;
&#xD;
      You will have transfusions of blood and platelets as needed.&#xD;
&#xD;
      Study Groups A and B:&#xD;
&#xD;
      About 1 month after the transplant, you will be randomly assigned (as in the toss of a coin)&#xD;
      to 1 of 2 new groups (Group A and Group B). Group A will receive rituximab by vein over 5-7&#xD;
      hours, once every 3 months, starting 3 months after the stem cell transplant. You will&#xD;
      receive rituximab for the first 18 months after the stem cell transplant. Group B will not&#xD;
      receive rituximab. You will have an equal chance of being in each group.&#xD;
&#xD;
      Follow-up Visits:&#xD;
&#xD;
      You will return to the clinic every 6 months for 5 years to check the status of the disease.&#xD;
      The following tests and procedures will be performed:&#xD;
&#xD;
        -  Blood (about 1-2 tablespoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have a bone marrow biopsy to check the status of the disease.&#xD;
&#xD;
        -  You will have a chest x-ray and a CT scan.&#xD;
&#xD;
        -  You will have a PET scan.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may stay on study as long as you are benefitting. You will be taken off-study if the&#xD;
      disease gets worse or intolerable side effects occur.&#xD;
&#xD;
      This is an investigational study. 90Y-Zevalin is approved by the FDA for relapsed and&#xD;
      refractory lymphoma. Its use in this study is investigational. 111In Zevalin, Carmustine,&#xD;
      etoposide, cytarabine, melphalan, and Rituximab are all FDA approved and commercially&#xD;
      available. However, their use together in this study is also investigational. Up to 50&#xD;
      patients will be take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2007</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a 2-Year Progression-Free Survival (PFS)</measure>
    <time_frame>2 years (beginning day 30 after treatment)</time_frame>
    <description>Response evaluated using the standard criteria response for lymphoma through CT scan.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BEAM + Rituximab Followed by Stem Cell Transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zevalin</intervention_name>
    <description>(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.</description>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <other_name>Ibritumomab</other_name>
    <other_name>IDEC-Y2B8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>300 mg/m^2 by vein.</description>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>BiCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>200 mg/m^2 by vein every 12 hours.</description>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>200 mg/m^2 by vein every 12 hours.</description>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrocholoride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2 by vein.</description>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.</description>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Injection of stem cells (Autologous SCT)</description>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant</arm_group_label>
    <arm_group_label>BEAM + Rituximab + Stem Cell Transplant + Rituximab</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant</arm_group_label>
    <arm_group_label>Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab</arm_group_label>
    <other_name>Stem Cell Transplantation</other_name>
    <other_name>SCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed CD20-positive B-cell diffuse large cell lymphoma (demonstrated in lymph nodes&#xD;
             or bone marrow), chemosensitive (at least PR).&#xD;
&#xD;
          2. Age: up to 18-70 years of age.&#xD;
&#xD;
          3. Prestudy performance status of 0, 1, or 2 according to the WHO.&#xD;
&#xD;
          4. No anti-cancer therapy started within three weeks, prior to study initiation, and&#xD;
             fully recovered from all toxicities associated with prior surgery, radiation&#xD;
             treatments, chemotherapy, or immunotherapy. No prior rituximab within three weeks of&#xD;
             starting therapy.&#xD;
&#xD;
          5. If patients had prior radiation, this should have not involved more than 25% of the&#xD;
             bone marrow.&#xD;
&#xD;
          6. Acceptable hematologic status within two weeks prior to patient registration,&#xD;
             including: Absolute neutrophil count ({segmented neutrophils + bands} x total WBC) &gt;&#xD;
             1,500/mm³ and platelet counts &gt; 80,000/mm³&#xD;
&#xD;
          7. IRB -approved signed informed consent.&#xD;
&#xD;
          8. Patients determined to have &lt;10% bone marrow involvement with lymphoma within 60 days&#xD;
             before study entry as defined by bone marrow aspirates and biopsies.&#xD;
&#xD;
          9. Female patients included must not be pregnant or lactating.&#xD;
&#xD;
         10. Patients should have at least 4-6 x 10^6 CD34+/kg peripheral stem cells collected.&#xD;
             Around 1-2 million cells will beheld as back up.&#xD;
&#xD;
         11. Voluntary signed, written IRB-approved informed consent before performance of any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             consent may be withdrawn by the subject at any time without prejudice to future&#xD;
             medical care.&#xD;
&#xD;
         12. Men and women of reproductive potential must agree to follow accepted birth control&#xD;
             methods for the duration of the study. Female subject is either post-menopausal or&#xD;
             surgically sterilized or willing to use an acceptable method of birth control (i.e., a&#xD;
             hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with&#xD;
             spermicide, or abstinence) for the duration of the study. Male subject agrees to use&#xD;
             an acceptable method for contraception for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failed stem cell collection of &gt;/= 4x10^6CD34+/kg.&#xD;
&#xD;
          2. Prior radioimmunotherapy.&#xD;
&#xD;
          3. Presence of active CNS lymphoma.&#xD;
&#xD;
          4. Patients with abnormal liver function: total bilirubin &gt; 1.5 mg/dl.&#xD;
&#xD;
          5. Patients with abnormal renal function: serum creatinine &gt; 1.6 mg/dl.&#xD;
&#xD;
          6. Serious nonmalignant disease or infection which, in the opinion of the investigator&#xD;
             and/or the sponsor, would compromise other protocol objectives.&#xD;
&#xD;
          7. Corrected DLCO &lt; 50% and FEV subscript 1 or FVC &lt; 50% predicted.&#xD;
&#xD;
          8. Cardiac EF &lt; 50% by 2-D Echogram.&#xD;
&#xD;
          9. Prior radiation to lungs.&#xD;
&#xD;
         10. Abnormal cytogenetics predictive of secondary cancers, such as -5,-7.&#xD;
&#xD;
         11. Pregnant (Positive Beta HCG test in a woman with child bearing potential defined as&#xD;
             not post-menopausal for 12 months or no previous surgical sterilization) or currently&#xD;
             breast-feeding. Pregnancy testing is not required for post-menopausal or surgically&#xD;
             sterilized women.&#xD;
&#xD;
         12. Patients with other malignancies diagnosed within 2 years prior to Study entry (except&#xD;
             skin squamous or basal cell carcinoma).&#xD;
&#xD;
         13. Active uncontrolled bacterial, viral fungal infections.&#xD;
&#xD;
         14. Major surgical procedure or significant traumatic injury within 4 weeks prior to Study&#xD;
             entry.&#xD;
&#xD;
         15. Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         16. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 3 months prior to Study entry.&#xD;
&#xD;
         17. History of Stroke within 6 months.&#xD;
&#xD;
         18. Myocardial infarction within the past 6 months prior to Study Day 1, or has New York&#xD;
             Heart Association (NYHA) Class III or IV heart failure or arrythmias, unstable angina,&#xD;
             uncontrolled congestive heart failure or arrythmias, or electrocardiographic evidence&#xD;
             of acute ischemia or active conduction system abnormalities. Prior to study entry, any&#xD;
             ECG abnormality at screening must be documented by investigator as not medically&#xD;
             relevant.&#xD;
&#xD;
         19. Uncontrolled chronic diarrhea.&#xD;
&#xD;
         20. Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>January 12, 2021</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse Large Cell Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Zevalin</keyword>
  <keyword>Ibritumomab</keyword>
  <keyword>IDEC-Y2B8</keyword>
  <keyword>Carmustine</keyword>
  <keyword>BCNU</keyword>
  <keyword>BiCNU</keyword>
  <keyword>Etoposide</keyword>
  <keyword>VePesid</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>BEAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT00591630/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant</title>
          <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="P2">
          <title>Group 1 - Zevalin + BEAM + Stem Cell Transplant</title>
          <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="P3">
          <title>Group 2 - BEAM + Rituximab + Stem Cell Transplant</title>
          <description>BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="P4">
          <title>Group 2 - BEAM + Stem Cell Transplant</title>
          <description>BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant</title>
          <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="B2">
          <title>Group 1 - Zevalin + BEAM + Stem Cell Transplant</title>
          <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="B3">
          <title>Group 2 - BEAM + Rituximab + Stem Cell Transplant</title>
          <description>BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="B4">
          <title>Group 2 - BEAM + Stem Cell Transplant</title>
          <description>BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a 2-Year Progression-Free Survival (PFS)</title>
        <description>Response evaluated using the standard criteria response for lymphoma through CT scan.</description>
        <time_frame>2 years (beginning day 30 after treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant</title>
            <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 - Zevalin + BEAM + Stem Cell Transplant</title>
            <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 - BEAM + Rituximab + Stem Cell Transplant</title>
            <description>BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 - BEAM + Stem Cell Transplant</title>
            <description>BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a 2-Year Progression-Free Survival (PFS)</title>
          <description>Response evaluated using the standard criteria response for lymphoma through CT scan.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant</title>
          <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="E2">
          <title>Group 1 - Zevalin + BEAM + Stem Cell Transplant</title>
          <description>Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="E3">
          <title>Group 2 - BEAM + Rituximab + Stem Cell Transplant</title>
          <description>BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
        <group group_id="E4">
          <title>Group 2 - BEAM + Stem Cell Transplant</title>
          <description>BEAM + Rituximab Followed by Stem Cell Transplant&#xD;
Carmustine: 300 mg/m^2 by vein.&#xD;
Etoposide: 200 mg/m^2 by vein every 12 hours.&#xD;
Cytarabine: 200 mg/m^2 by vein every 12 hours.&#xD;
Melphalan: 140 mg/m^2 by vein.&#xD;
Rituximab: Arm 1, Arm 2 = 250 mg/m^2 by vein;&#xD;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;&#xD;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.&#xD;
Stem Cell Transplant: Injection of stem cells (Autologous SCT)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CD OTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NE OTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding (no GI no PUL)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CD OTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flu like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>IN FEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALK increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>T bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NE COR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NE OTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issa F. Khouri, MD / Stem Cell Transplantation</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-8750</phone>
      <email>ikhouri@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

